Zeroing In On A KillerNeil Gross
Before Washington budget-cutters hack any deeper into science spending, they should consider the short history of Alzheimer's disease research. Scientists have yet to produce a cure for this killer, which afflicts 4 million Americans. And controversies still rage over what triggers AD's complex progression of interlinked disorders.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.